Herr H W
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
J Urol. 2000 Jan;163(1):60-1; discussion 61-2.
Tumor progression and survival of patients with high grade Ta bladder tumors followed for 15 to 20 years were evaluated.
A total of 148 patients with Ta and 73 with T1 multiple, recurrent papillary bladder tumors were evaluated. In all patients complete transurethral resection was performed and 1 or more courses of bacillus Calmette-Guerin therapy were given. Minimum followup was 15 years. Of the Ta tumors 125 were high grade and 23 were low grade. The end points of the study were stage progression, defined as lamina propria invasion, muscle invasion or metastasis, and disease specific survival.
The 15-year progression-free survival rate was 95% in the 23 patients with low grade Ta tumors and none died of disease. Progression-free survival and disease specific survival rates were 61% and 74%, respectively, in 125 patients with high grade Ta tumors compared to 44% and 62%, respectively, in 73 with T1 tumors.
Patients with high grade Ta tumors have a lifelong risk of disease stage progression and death from bladder cancer similar to those with T1 tumors.
评估随访15至20年的高级别Ta期膀胱肿瘤患者的肿瘤进展情况和生存率。
共评估了148例Ta期和73例T1期多发性复发性乳头状膀胱肿瘤患者。所有患者均接受了经尿道完全切除术,并给予1个或更多疗程的卡介苗治疗。最短随访时间为15年。Ta期肿瘤中,125例为高级别,23例为低级别。研究的终点为分期进展(定义为固有层浸润、肌层浸润或转移)和疾病特异性生存。
23例低级别Ta期肿瘤患者的15年无进展生存率为95%,无患者死于该疾病。125例高级别Ta期肿瘤患者的无进展生存率和疾病特异性生存率分别为61%和74%,而73例T1期肿瘤患者的相应比例分别为44%和62%。
高级别Ta期肿瘤患者与T1期肿瘤患者一样,终生都有疾病分期进展和死于膀胱癌的风险。